1. LBA 2Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial. (13th May 2019) Authors: Guarneri, V; Cinieri, S; Orlando, L; Bengala, C; Mariani, G; Bisagni, G; Frassoldati, A; Zamagni, C; Salvo, G De; Conte, P F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗